Development of targeted protein degradation therapeutics
Crossref DOI link: https://doi.org/10.1038/s41589-019-0362-y
Published Online: 2019-09-16
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chamberlain, Philip P.
Hamann, Lawrence G.
Text and Data Mining valid from 2019-09-16
Version of Record valid from 2019-09-16
Article History
Received: 11 April 2019
Accepted: 5 August 2019
First Online: 16 September 2019
Competing interests
: The authors are employees and shareholders of Celgene.